Elicio Therapeutics Inc. (ELTX) - Total Liabilities
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has total liabilities worth $23.39 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Elicio Therapeutics Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Elicio Therapeutics Inc. - Total Liabilities Trend (2012–2025)
This chart illustrates how Elicio Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Elicio Therapeutics Inc. total assets.
Elicio Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Elicio Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Q.S.I Co. LTD
KQ:066310
|
Korea | ₩4.82 Billion |
|
Bever Holding NV
AS:BEVER
|
Netherlands | €13.49 Million |
|
Matrix Composites & Engineering Ltd
AU:MCE
|
Australia | AU$51.45 Million |
|
Tadir-Gan (Precision Products) 1993 Ltd
TA:TDGN
|
Israel | ILA16.78 Million |
|
Shenzhen SEG Co Ltd
SHE:200058
|
China | HK$2.44 Billion |
|
Uniflex Technology Inc
TW:3321
|
Taiwan | NT$1.38 Billion |
|
Children’s Place Inc
NASDAQ:PLCE
|
USA | $836.41 Million |
|
Syntek Semiconductor Co Ltd
TWO:5302
|
Taiwan | NT$534.33 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Elicio Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Elicio Therapeutics Inc. net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elicio Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual total liabilities of Elicio Therapeutics Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $24.23 Million | -38.65% |
| 2024-12-31 | $39.49 Million | +150.36% |
| 2023-12-31 | $15.77 Million | +14.72% |
| 2022-12-31 | $13.75 Million | -8.38% |
| 2021-12-31 | $15.01 Million | -89.11% |
| 2020-12-31 | $137.80 Million | +352.21% |
| 2019-12-31 | $30.47 Million | +294.87% |
| 2018-12-31 | $7.72 Million | +16.87% |
| 2013-12-31 | $6.60 Million | -2.78% |
| 2012-12-31 | $6.79 Million | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more